JNJ vs SNDX

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Syndax shows strong commercial momentum with Revuforj and Niktimvo sales annualizing near $200 million each, validating its market opportunity in oncology with 224% YoY revenue growth. The significant narrowing of net loss in Q1 2026, beating EPS estimates, addresses prior profitability concerns and indicates a better path towards sustainable operations, despite a minor revenue miss. The company m...